Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2007

View Archived Issues

Novel recombinant poxvirus vaccine candidates immunogenic against HIV antigens in mice

HuMAb 17C7: a new monoclonal antibody against rabies

Novel anticancer compounds reported in recent patent literature

Tasquinimod enhances response to androgen ablation in prostate cancer models

GlaxoSmithKline reports on novel compounds with in vitro activity against human papilloma virus

Recent Tokai University and Sankyo patent covers new therapeutic agents for renal disorders

Novel VLA-1 antagonists presented at the recent ACS meeting

New treatment options for gastrointestinal disorders disclosed in recent patent literature

Enrollment progresses in phase III study of Rencarex

Vicinium studied in phase II for locally persistent noninvasive bladder cancer

SuperGen completes sale of remaining Nipent rights

Lilly withdraws E.U. marketing authorization application for Arxxant

Wyeth brings to 100% its ownership stake in Wyeth K.K. Japan

Surface Logix closes second tranche of Series D financing

Acomplia approved in Switzerland

Taxus Express2 paclitaxel-eluting coronary stent system approved in Japan

Proellex improves symptoms associated with uterine fibroids

Final median survival data from phase II GVAX prostate cancer study

Glycopyrrolate begins pivotal safety study in pediatric drooling

LX-201 begins pivotal trials

Femathina studied for endometrial thinning in new phase II trial

MB-07803 begins proof-of-concept study in type 2 diabetes

Roche to acquire Bioveris

Basiliximab studied for ulcerative colitis in phase IIb trial

Ceflatonin studied in new phase II/III study in CML

FDA approves new coated Niaspan tablet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.